Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-5339 in Advanced Solid Tumors and Lymphomas
NCT04372641Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CB-5339 in solid tumor and lymphoma, sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events at 30 days and Recommended phase II dose at 30 days. Planned start Jun 2020; status: withdrawn.
02
Drugs
CB-5339
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT04372641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372641.